GALNT2, an O-glycosylating enzyme, is a critical regulator of radioresistance of non-small cell lung cancer: evidence from an integrated multi-omics analysis

被引：0
|
作者：
Xiaoxia Dong
Yahui Leng
Tian Tian
Qing Hu
Shuang Chen
Yufeng Liu
Li Shen
机构：
[1] Hubei University of Medicine,Department of Clinical Oncology, Taihe Hospital
[2] Hubei University of Medicine,Institute of Basic Medical Sciences
来源：
Cell Biology and Toxicology | 2023年 / 39卷
关键词：
NSCLC; Multi-omics; Glycosylation; GALNT2; Radioresistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3159 / 3174
页数：15
相关论文
共 20 条
  • [11] Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
    Stefania Volpe
    Mattia Zaffaroni
    Gaia Piperno
    Maria Giulia Vincini
    Maria Alessia Zerella
    Federico Mastroleo
    Federica Cattani
    Cristiana Iuliana Fodor
    Federica Bellerba
    Tiziana Bonaldi
    Giuseppina Bonizzi
    Francesco Ceci
    Marta Cremonesi
    Nicola Fusco
    Sara Gandini
    Cristina Garibaldi
    Davide La Torre
    Roberta Noberini
    Giuseppe Petralia
    Lorenzo Spaggiari
    Konstantinos Venetis
    Roberto Orecchia
    Monica Casiraghi
    Barbara Alicja Jereczek-Fossa
    BMC Cancer, 23
  • [12] Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
    Volpe, Stefania
    Zaffaroni, Mattia
    Piperno, Gaia
    Vincini, Maria Giulia
    Zerella, Maria Alessia
    Mastroleo, Federico
    Cattani, Federica
    Fodor, Cristiana Iuliana
    Bellerba, Federica
    Bonaldi, Tiziana
    Bonizzi, Giuseppina
    Ceci, Francesco
    Cremonesi, Marta
    Fusco, Nicola
    Gandini, Sara
    Garibaldi, Cristina
    Torre, Davide La
    Noberini, Roberta
    Petralia, Giuseppe
    Spaggiari, Lorenzo
    Venetis, Konstantinos
    Orecchia, Roberto
    Casiraghi, Monica
    Jereczek-Fossa, Barbara Alicja
    BMC CANCER, 2023, 23 (01)
  • [13] Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice
    Taverna, Simona
    Giallombardo, Marco
    Gil-Bazo, Ignacio
    Carreca, Anna Paola
    Castiglia, Marta
    Chacartegui, Jorge
    Araujo, Antonio
    Alessandro, Riccardo
    Pauwels, Patrick
    Peeters, Marc
    Rolfo, Christian
    ONCOTARGET, 2016, 7 (19) : 28748 - 28760
  • [14] Multi-Omic Analysis Between Tumor Tissues from Early and Late Stage Non-Small Cell Lung Cancer Patients
    Zhang, B.
    Yue, D.
    Gao, L.
    Li, C.
    Xiao, S.
    Pu, Y.
    Lin, R.
    Wang, T.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S538 - S539
  • [15] Integrated network pharmacology and experimental analysis unveil multi-targeted effect of 18a-glycyrrhetinic acid against non-small cell lung cancer
    Irshad, Rasha
    Raj, Nafis
    Gabr, Gamal A.
    Manzoor, Nikhat
    Husain, Mohammad
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [16] MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis
    Huang, Xing
    Sun, Qi
    Chen, Chen
    Zhang, Yi
    Kang, Xin
    Zhang, Jing-Yuan
    Ma, Da-Wei
    Xia, Lei
    Xu, Lin
    Xu, Xin-Yu
    Ren, Bin-Hui
    ONCOTARGET, 2017, 8 (52) : 90315 - 90326
  • [17] Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative
    Soares, Marta
    Antunes, Luis
    Redondo, Patricia
    Borges, Marina
    Hermans, Ruben
    Patel, Dony
    Grimson, Fiona
    Munro, Robin
    Chaib, Carlos
    Lacoin, Laure
    Daumont, Melinda
    Penrod, John R.
    O'Donnell, John C.
    Bento, Maria Jose
    Rocha Goncalves, Francisco
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [18] Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
    Xingsheng Hu
    Shucai Zhang
    Zhiyong Ma
    Jifeng Feng
    Lin Wu
    Dongqing Lv
    Jianying Zhou
    Xiaodong Zhang
    Li Liu
    Qitao Yu
    Wangjun Liao
    Yiping Zhang
    Xiang Wang
    Ying Cheng
    Hongrui Niu
    Ziping Wang
    Dong Wang
    Cheng Huang
    Chunling Liu
    Hui Zhao
    Jian Feng
    Jingzhang Li
    Kejing Ying
    Nong Yang
    Shukui Qin
    Jie Hu
    Fei Liu
    Yong Jiang
    Nan Ge
    Yuankai Shi
    BMC Medicine, 21
  • [19] Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
    Hu, Xingsheng
    Zhang, Shucai
    Ma, Zhiyong
    Feng, Jifeng
    Wu, Lin
    Lv, Dongqing
    Zhou, Jianying
    Zhang, Xiaodong
    Liu, Li
    Yu, Qitao
    Liao, Wangjun
    Zhang, Yiping
    Wang, Xiang
    Cheng, Ying
    Niu, Hongrui
    Wang, Ziping
    Wang, Dong
    Huang, Cheng
    Liu, Chunling
    Zhao, Hui
    Feng, Jian
    Li, Jingzhang
    Ying, Kejing
    Yang, Nong
    Qin, Shukui
    Hu, Jie
    Liu, Fei
    Jiang, Yong
    Ge, Nan
    Shi, Yuankai
    BMC MEDICINE, 2023, 21 (01)
  • [20] The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating p105 fraction of the HER-2/neu proto-oncogene:: In vivo evidence from patients with advanced non-small cell lung cancer (NSCLC)
    Jumper, C
    Cobos, E
    Lox, C
    ANTICANCER RESEARCH, 2002, 22 (04) : 2073 - 2076
12